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Background: Evidence from longitudinal studies on the impact of exacerbation symptoms 
on physical activity in chronic obstructive pulmonary disease (COPD) is lacking. The aim of 
this first exploratory study was to assess the association between exacerbation symptoms and 
physical activity, and to quantify the relative influence of specific symptoms.
Methods: We recruited COPD patients at high risk for exacerbations from 2 pulmonary 
rehabilitation clinics and 1 acute care clinic in Switzerland. For 3 months after discharge, patients 
completed a daily symptom diary on a smartphone application, the EXAcerbations of Chronic 
pulmonary disease Tool (EXACT), and wore a pedometer to measure daily steps. We used mixed-
effects models to determine the association of daily steps with exacerbation symptoms.
Results: A total of 21 patients (Global Initiative for Chronic Obstructive Lung Disease 
grades 2–4) were enrolled for a mean of 94.4 days (standard deviation 4.2). The baseline 
median number of daily steps was 3,264.6 (interquartile range [IQR]: 1,851.3–4,784.1) and 
EXACT score was 37.0 (IQR: 30.9–41.4). A 12-point increase in EXACT score (indicating 
the start of an exacerbation) was statistically significantly associated with a decrease in daily 
steps of 653.3 (95% CI 969.7–336.9). Chest symptoms (tightness, discomfort and congestion) 
were more strongly associated with change in steps than breathlessness, and cough and sputum 
(z-value −4.5 vs −2.9 and −3.0).
Conclusion: This is the first study to show that, in a small cohort of COPD patients, increases 
in exacerbation symptoms were associated with a statistically and clinically significant reduc-
tion in daily physical activity. These results underscore the importance for symptom control 
and exacerbation prevention in COPD patients.
Keywords: longitudinal, management, step count, PRO, COPD, exacerbation, physical activity, 
symptoms
Introduction
Physical inactivity and exacerbations are both prominent features in chronic obstructive 
pulmonary disease (COPD) patients. They have been independently linked to outcomes 
including reduced health-related quality of life and increased morbidity and mortality.1–4 
Physical activity is potentially modifiable and known determinants include age, sex 
and exercise capacity;5 however, there is still much to learn about factors influencing 
physical activity levels.3
The relationship between exacerbations of COPD and physical activity is com-
plex and currently not well understood. Low activity levels are a strong predictor of 
future severe exacerbations;6–10 however, physical activity is also known to be reduced 
during exacerbations.11–13 Exacerbations are characterized by a worsening of the 
Correspondence: anja Frei
Department of epidemiology, 
epidemiology, Biostatistics and 
Prevention Institute, University 
of Zurich, hirschengraben 84, 
Zurich 8001, switzerland
Tel +41 44 634 4360
email anja.frei@uzh.ch 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2018
Volume: 13
Running head verso: Crook et al
Running head recto: Daily symptoms of exacerbation and physical activity in COPD
DOI: 156986
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2200
Crook et al
patient’s respiratory symptoms beyond the normal day-to-
day variability;14 however, there are a few studies published 
on exacerbation symptoms in relation to physical activity. 
Exacerbation symptoms such as increased cough, sputum 
production, dyspnea and chest congestion could plausibly 
limit patients’ ability and/or willingness to be active. A recent 
systematic review found little evidence on the association 
between symptoms of COPD and objectively measured 
physical activity.15 One cross-sectional study reported statisti-
cally significant relationships between symptoms at different 
times of the day and subjectively assigned physical activity 
levels at baseline,16 and two studies found that reporting a 
sore throat was associated with a decline in physical activity 
during an exacerbation.12,17
However, to our knowledge the impact of specific symp-
toms on changes in physical activity has not been explicitly 
assessed in longitudinal studies beyond limited periods of 
time (ie, during hospitalization). As exacerbation symptoms 
are known to naturally vary daily both inside and outside of 
exacerbation periods,18 it is important to capture the relation-
ship between symptoms and physical activity longitudinally 
across the natural course of COPD. Therefore, we aimed to 
investigate the association between exacerbation symptoms 
and physical activity in COPD patients, and to quantify the 
relative influence of specific respiratory symptoms.
Methods
study design and population
We recruited patients from 2 pulmonary rehabilitation clin-
ics (Klinik Barmelweid and Zürcher RehaZentrum Wald) 
and 1 acute care clinic (Stadtspital Waid) in Switzerland 
(ClinicalTrials.gov: NCT02441725). In Switzerland, patients 
follow an inpatient rehabilitation program typically just 
after suffering from an exacerbation, and these patients 
usually have moderate to very severe COPD and multiple 
comorbidities. Thus, the patients included in this study 
were at high risk for additional exacerbations. We recruited 
patients from these settings as they were more likely to expe-
rience exacerbations during the study period. Patients from 
the pulmonary rehabilitation clinics already participated in 
the Validation of the 1-minute Sit-to-Stand Test in Patients 
with COPD (STAND-UP) study,19 with assessments during 
rehabilitation. They then decided whether to participate in 
the present study, the extended part of the STAND-UP study 
with additional assessments for 3 months after discharge. We 
included male and female patients $40 years of age with a 
COPD diagnosis according to Global Initiative for Chronic 
Obstructive Lung Disease criteria (post-bronchodilator forced 
expiratory volume in 1 s [FEV
1
]/forced vital capacity,70%). 
Patients were not included if the enrolling physician deemed 
them to have cognitive reading impairment and/or difficulties 
managing a smartphone or step counter that would limit their 
ability to complete the study assessments. Other exclusion 
criteria were lower limb joint surgery in the preceding 3 
months, predominant neurological or musculoskeletal limi-
tation to walking and inability to do five repetitions in the 
1-minute sit-to-stand test.
This study was approved by all local ethics commit-
tees (Kantonale Ethikkommission Zürich [2014-0614] and 
Ethikkommission Nordwest-und ZentralSchweiz [2015-
095]). All patients gave their written and oral informed 
consent to participate.
Daily assessments
Every evening before going to bed, participants completed 
the EXAcerbations of Chronic pulmonary disease Tool 
(EXACT) on a smartphone application, which is a validated 
14-item symptom diary.20 The EXACT diary was developed 
and validated in a multistep process by the EXACT-PRO 
Initiative®. EXACT aims to provide a direct measure of 
exacerbation symptoms to evaluate the frequency, severity 
and duration of exacerbations in COPD patients. It asks about 
symptoms including cough, sputum production, dyspnea, 
chest symptoms (tightness, discomfort and congestion), tired-
ness, weakness, sleep disturbance and psychological state, 
and participants answer based on the symptoms experienced 
that day. The total EXACT score reflects the entirety of the 
symptoms on a scale of 0–100, with higher scores indicating 
more severe symptoms.20,21 An increase from baseline of 9 
(for 3 days) or 12 points (for 2 days) is used to identify the 
start of an EXACT event (symptom-defined exacerbation). 
The Evaluating Respiratory Symptoms in COPD (E-RS) tool 
is a validated sub-scale of the EXACT, which reflects the 
specific respiratory symptoms experienced in three domains 
(breathlessness [scale 0–17, 5 items], cough and sputum 
[0–11, 3 items], and chest symptoms [0–12, 3 items]).22,23 
Participants were given a study smartphone to use if they 
did not have/wish to use their own.
Participants wore a pedometer (Fitbug Air; Fitbug, 
London, UK) on the hip for 3 months, at all times, except 
when sleeping or showering/swimming. They were asked to 
transfer the steps data each evening to the Fitbug smartphone 
application; if 1 or more days were missed, steps data were 
stored on the pedometer for 14 days. We trained participants 
to use the smartphone, the EXACT application, and to trans-
fer the steps data. To maximize compliance, data transfers 
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were monitored by study staff and participants were contacted 
if $3 days were missed.
event-based exacerbations and adverse 
events
Exacerbations and adverse events were assessed with 
monthly telephone calls that were made to the patient by an 
experienced study nurse. The event-based definition required 
an increase in symptoms and an increase in dosage of or new 
prescription of systemic corticosteroids and/or antibiotics.
statistical analyses
Data were expressed as mean ± standard deviation (SD) or 
median (interquartile range [IQR]), depending on the data 
distribution. We used linear mixed-effects models with daily 
step count as the outcome, with a random intercept by subjects 
and a random slope to account for the repeated measurements 
of exacerbation symptoms and step count within patients. To 
investigate exacerbation symptoms and physical activity, we 
fitted a model with the daily total EXACT score as the expo-
sure variable and the random slope (model 1). We fitted three 
further models, one for each E-RS domain as the exposure 
variable and random slope, to investigate the relative influ-
ence of different respiratory symptoms (models 2–4). All 
models were adjusted for relevant covariates that we identi-
fied from clinical experience and previous research3,5 (age, 
sex, FEV
1
 [L], body mass index, number of exacerbations in 
the previous year, number of comorbidities, smoking status 
and functional exercise capacity [1-minute sit-to-stand test 
repetitions]). All models were estimated with an unstructured 
covariance structure to allow for correlation between the two 
random effects. Due to heteroskedasticity of the residuals, 
we used a robust variance estimator to estimate the standard 
errors. For model 1, we estimated the change in daily steps in 
relation to a change in EXACT score of 12 points and 9 points, 
and for all models we calculated the z-value and Bayesian 
Information Criterion (BIC). Analyses were conducted using 
Stata (version 14.1; StataCorp, College Station, TX, USA).
Results
Population characteristics
In total, 22 patients from 2 pulmonary rehabilitation clinics 
(n=19) and 1 acute care hospital (n=3) with moderate to 
very severe COPD were included in the study. One patient 
withdrew from the study after baseline assessment due to a 
lack of motivation. Patients were followed up for a mean of 
94.4 (SD 4.2) days. Table 1 summarizes the baseline patient 
characteristics.
Baseline outcomes and adverse events
Participants had a mean of 85.3 (SD 17.3) days of step counts 
and 77.7 (SD 20.1) days of EXACT scores. Eleven event-
based exacerbations (9 home-based and 2 hospital-based) 
were experienced by 9 patients, and 10 adverse events were 
experienced by 6 patients (all unrelated to the study assess-
ments, non-serious and did not require hospitalization). The 
median (IQR) baseline daily step count was 3,264.6 (1,851.3–
4,784.1) and EXACT score was 37.0 (30.9–41.4), calculated 
as the median daily value of a stable period of 7 days (first 
week after discharge for pulmonary rehabilitation patients 
and second week after discharge for acute care patients). The 
EXACT scoring algorithm used to determine a symptom-
defined exacerbation did not detect .50% of the event-based 
exacerbations in our data. These results reflect those found 
previously in an independent validation of the EXACT scoring 
algorithm.24 Therefore, we did not consider symptom-defined 
exacerbations in the interpretation of our data.
exacerbation symptoms
Table 2 shows the adjusted coefficient for the association 
between daily EXACT score and daily step count, along 
Table 1 Patient characteristics at discharge from pulmonary 
rehabilitation or acute care
Characteristics Patients (N=21)
sex, male, n (%) 14 (66.7)
age (years) 63.0 (9.9)
FeV1 (l) 1.2 (0.4)
FeV1 % predicted 40.8 (14.3)
BMI (kgm−2) 23.9 (6.1)
smoking status, n (%)
never-smoker 1 (4.8)
Former smoker 15 (71.4)
Current smoker 5 (23.8)
gOlD grade, n (%)
II 5 (23.8)
III 8 (38.1)
IV 8 (38.1)
exacerbations in previous year 2.3 (1.9)
number of comorbidities per patient 3.4 (1.9)
Comorbidity type, n
Cardiovascular disease group 25
Cerebrovascular disease group 1
Metabolic disease group 1
Musculoskeletal disease group 5
Psychiatric disease group 6
Other diseases 31
1-min sTs test repetitions 22.4 (8.0)
Note: Data are presented as mean (sD), unless otherwise stated.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 s; 
gOlD, global Initiative for Chronic Obstructive lung Disease; 1-min sTs, 1-minute 
sit-to-stand.
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with the coefficients for each covariate. A 9-point increase 
in daily EXACT score was associated with a significant 
decrease of −490.0 (95% CI −727.3 to −252.7) in the number 
of daily steps. A 12-point increase in daily EXACT score 
was associated with a decrease of −653.3 (95% CI −969.7 
to −336.9) in the number of daily steps. In model 1, the 
adjusted intraclass correlation coefficient was 0.25. This 
means that most of the variation in daily steps (75%) was 
within individuals and only 25% was between individuals. 
The fitted regression lines from model 1 show the predicted 
association between daily exacerbation symptoms and daily 
steps for each patient (Figure 1). There is variation between 
patients in the estimated intercept and slope of the associa-
tion. There also appears to be a weaker association (slope 
more horizontal) at higher numbers of steps, and more 
between-patient variation at lower EXACT scores (fewer 
symptoms).
All three domains of the E-RS were independently signifi-
cantly associated with the number of daily steps in adjusted 
models (Table 3). The standardized regression coefficients 
show that the effect of chest symptoms on the number of 
daily steps was stronger than the effects of breathlessness, and 
cough and sputum (adjusted z-value −4.5 vs −2.9 and −3.0, 
respectively). The BIC was lowest for the model with chest 
symptoms, indicating there is a better fit of the data (lower 
BIC) than the models with the breathlessness and cough 
and sputum domains (breathlessness +17 and cough and 
sputum +12, compared to chest symptoms).
Individual patient courses of daily steps and daily EXACT 
scores over the 3-month study period are shown in Figure 2. 
Step count and EXACT score are presented as 5-day moving 
averages to facilitate the visualization of trends.
Discussion
In this novel study, we found that an increase in exacerbation 
symptoms was strongly associated with a reduction in physi-
cal activity. The strength of this association was found to dif-
fer between patients. Chest symptoms (tightness, discomfort 
and congestion) were more strongly associated with changes 
in physical activity than other respiratory symptoms.
To our knowledge, this is the first study to investigate 
the impact of exacerbation symptoms on changes in physical 
Table 2 Multivariable analysis assessing the association between daily eXaCT score and daily physical activity, adjusted for relevant 
confounders (model 1)
Variable Effect 95% CI z-value P-value
Daily eXaCT scorea
1 point increase −54.4 −80.8 to −28.1 −4.1 ,0.001
9 point increase −490.0 −727.3 to −252.7 −4.1 ,0.001
12 point increase −653.3 −969.7 to −336.9 −4.1 ,0.001
age (years) 1.0 −36.0 to 37.9 0.1 0.96
sex (ref: male)
Female 74.3 −952.3 to 1,101.0 0.1 0.89
FeV1 (l) 820.7 145.5 to 1,496.0 2.4 0.02
BMI (kgm−2) −34.8 −112.8 to 43.1 −0.9 0.38
1-min sTs test repetitions 49.6 −2.5 to 101.7 1.9 0.06
number of comorbidities per patient −471.7 −717.1 to −226.2 −3.8 ,0.001
smoking status (ref: current-smoker)
Former smoker 1,070.0 73.7 to 2,066.3 2.1 0.04
non-smoker 3,968.5 2,988.1 to 4,948.8 7.9 ,0.001
number of exacerbations in the previous year −8.3 −150.4 to 133.7 −0.1 0.91
Notes: ascore range: 0–100 points. Bayesian Information Criterion =25,709.
Abbreviations: BMI, body mass index; eXaCT, eXacerbations of Chronic pulmonary disease Tool; FeV1, forced expiratory volume in 1 s; 1-min sTs, 1-minute 
sit-to-stand; ref, reference.
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Figure 1 Fitted regression lines for individual patients for the association between 
daily step count and daily EXACT score from model 1. The figure shows the 
predicted number of daily steps for the given eXaCT score. There appears to be a 
weaker association (slope more horizontal) at higher numbers of steps, and more 
between-patient variation at lower eXaCT scores (fewer symptoms).
Abbreviation: eXaCT, eXacerbations of Chronic pulmonary disease Tool.
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Table 3 adjusteda associations of each respiratory symptom domain with daily physical activity, estimated from individual models 
(models 2–4)
E-RS symptom domain score Effect 95% CI z-value P-value BIC
Breathlessnessb (model 2) −153.4 −257.8 to −49.0 −2.9 0.004 25,748
Cough and sputumb (model 3) −127.8 −212.7 to −42.9 −3.0 0.003 25,743
Chest symptomsb,c (model 4) −187.7 −268.8 to −106.7 −4.5 ,0.001 25,731
Notes: aall 3 models were adjusted for the same confounders as in model 1; ball effects are per 1-point increase. Breathlessness score range: 0–17 points, cough and sputum 
score range: 0–11 points, chest symptoms score range: 0–12 points; cchest symptoms include chest tightness, discomfort and congestion.
Abbreviations: BIC, Bayesian Information Criterion; e-rs, evaluating respiratory symptoms in chronic obstructive pulmonary disease.
activity on a day-to-day basis. Patients were less likely to be 
active when they were experiencing exacerbation symptoms, 
resulting in a strong and statistically significant reduction in 
the number of steps walked. A clinically important increase 
in symptoms of exacerbation (an increase in total EXACT 
score of 12 points)20 was associated with a reduction of 
653 steps on that day. This reduction can be considered as 
clinically important as it exceeds the lower threshold of the 
recently estimated minimum important difference for daily 
step count (600–1,100 steps).25
Figure 2 (Continued)
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Figures 1 and 2 indicate that the strength of the association 
between exacerbation symptoms and physical activity differs 
among patients. Reasons for these inter-patient differences are 
currently unclear; however, there may be some influence from 
the average number of daily steps or overall variability in the 
number of daily steps, as suggested by the differences between 
estimated intercepts and slopes (Figure 1). It could be that 
patients with on average higher steps or with more variation 
in steps are influenced by exacerbation symptoms in a stronger 
manner, as their activity levels are able to reduce more than 
those who have an already low level, or it could be that another 
factor, such as severity of COPD, is driving the between-patient 
differences. One previous study found that patients with more 
daily and weekly variability in symptoms were more affected 
in their daily activities.18 However, this would need to be 
investigated in a larger study of COPD patients. The associa-
tion between EXACT score and number of steps is evident in 
some patients but is not always obvious (Figure 2). Patient 4 
is an example of a seemingly consistent negative correlation, 
whereas patient 2 appears to show little correlation. There is 
marked variability in exacerbation symptoms even in periods 
with no event-based exacerbation, which corresponds with 
a previous study that found daily and weekly variability in 
exacerbation symptoms in non-exacerbation periods.18
Previous research has shown that breathlessness and 
cough and sputum production are more commonly reported 
by COPD patients than chest discomfort and tightness.18,26 
More patients also perceived increasing cough, breathless-
ness and sputum to have a high impact on wellbeing than 
chest pain (42%, 37% and 35% vs 20% of respondents).26 
However, in our patients we found that an increase in 
chest symptoms had a more substantial impact on physical 
activity than breathlessness or cough and sputum. We can 
only speculate about the specific underlying cause of these 
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Figure 2 Individual courses of daily step count and daily total eXaCT score over the 3-month study period for patients who did not have an exacerbation (A) and patients who 
did have an exacerbation (B). Diamonds indicate the start date of clinically defined event-based exacerbations, gray boxes indicate the 28-day recovery period after the start of an 
exacerbation and black squares indicate adverse events (unrelated to COPD exacerbations). Patients 16 (14 days) and 19 (1 day) were admitted to hospital due to their exacerbations; 
all other exacerbations were home-based. adverse events were constipation (patient 5), numbness in feet (patient 7), purulent infection on the arm (8), stomach pain and diarrhea 
(14), electric cardioversion (16), severe sunburn to chest (18), tooth removal and armpit abscess (19) and crushed ribs (21). no adverse events required hospitalization.
Notes: numbers in the lower left-hand corner represent an individual patient (in random order).
Abbreviations: COPD, chronic obstructive pulmonary disease; eXaCT, eXacerbations of Chronic pulmonary disease Tool.
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symptoms, since a high number of patients in our study had 
cardiovascular comorbidities. Although EXACT was specifi-
cally developed in COPD patients to assess symptoms of 
respiratory exacerbations, it cannot differentiate the origins 
of the symptoms reported. Our results also differ from two 
studies where the only symptoms found to be associated 
with decline in physical activity were sore throat alone or 
sore throat and dyspnea or cough combined, although chest 
tightness, discomfort and congestion were not assessed and 
associations were only considered at exacerbation onset or 
during recovery.12,17 When considering symptoms in relation 
to interventions for improving physical activity levels in 
COPD patients, it may be important to target the reduction of 
chest symptoms, regardless of the underlying mechanism.
We have provided novel individual patient data on the 
association between daily symptoms and daily physical activity 
during a typical 3-month period. Previous research has focused 
on physical activity during or before exacerbations, or physical 
activity as a predictor for future exacerbations.6–9,11 Our study 
followed patients for 3 months, and therefore consists of peri-
ods of stability, exacerbation and recovery from exacerbation. 
Previous studies on the effect of exacerbations on physical 
activity have limited or categorized their analyses of physical 
activity to specific patient states (eg, only in stability or recov-
ery vs exacerbation).12,13,17,18,27 A strength of our study is that we 
considered the overall association using longitudinal analyses, 
including different patient states and therefore avoiding the loss 
of valuable information. A potential additional hypothesis that 
should be explored in a larger study using longitudinal data 
and methods is whether the observed association differs during 
periods of exacerbation and stability.
One limitation of our study is that there was some miss-
ing data for daily steps and EXACT scores, which is difficult 
to avoid in longitudinal studies with repeated assessments. 
In some instances, the data were missing due to technical 
problems with the smartphone and/or application (missing 
completely at random). However, the reason for missingness 
was often not clear. While the mixed-effects model accounts 
for missing repeated-measures data, it should be considered 
that there may be important information missing when the 
reason for missing values was related to the outcome (ie, 
patient not completing the EXACT questionnaire during an 
exacerbation). A second limitation is the small sample size, 
which limits our ability to investigate the association fur-
ther. This is partly explained by the substantial commitment 
patients need to have to report symptoms daily and wear a 
pedometer for 3 months. Despite this, we used longitudinal 
methods that enabled us to make use of the large amount 
of data collected over the study period. In total, model 1 
utilized around 1,500 observations. Therefore, we consider 
our results to be valid in this sample, and our results may be 
generalizable to other patients with moderate to very severe 
COPD following an exacerbation. From visual inspection of 
individual patient data, we generated further hypotheses con-
cerning the relationship between exacerbation symptoms and 
physical activity, although the small number of clusters 
limited our ability to explore these. Our use of pedometers 
to measure physical activity rather than accelerometers could 
be considered as a limitation since pedometers may under-
estimate steps in moderate to very severe COPD patients28,29 
and we do not have additional information on the intensity or 
duration of activity. However, as the patients in our study all 
had moderate to very severe COPD, it is likely that bias from 
underestimation of steps is similar across patients. Therefore, 
we decided to use the Fitbug Air as a simple tool for assessing 
physical activity, which has previously been used in studies 
of COPD patients,30 as it is more valid than self-reported 
questionnaires, has less burden for patients and can record 
activity over a longer period than accelerometers.31
Conclusion
An increase in daily exacerbation symptoms was statisti-
cally and clinically significantly associated with increasing 
physical inactivity in our population of COPD patients. 
Respiratory chest symptoms may be more important in 
determining physical inactivity levels than other respiratory 
symptoms. These novel results give us additional insight 
into the behavior of COPD patients in relation to changes 
in physical activity and emphasize the need for symptom 
control and prevention of exacerbations.
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